Table 2.
Clinical Trials Combining Epigenetic and Immune Therapy
| DNMTi | ICI | Condition | Phase | NCT Number |
|---|---|---|---|---|
| Azacitidine | Atezolizumab | MDS | I | NCT02508870 |
| Avelumab | AML, B-cell lymphoma | I, II, III | NCT03390296, NCT02953561, NCT02951156 | |
| Durvalumab | Colorectal carcinoma, ovarian cancer, breast cancer, T-cell lymphoma, AML, MDS, head and neck cancer, NSCLC | I, II | NCT02811497, NCT03161223, NCT02775903, NCT03019003, NCT02117219, NCT02281084, NCT02250326 | |
| Ipilimumab | Leukemia, MDS | II | NCT02530463, NCT02397720 | |
| Nivolumab | Leukemia, AML, Osteosarcoma, NSCLC, MDS | I, II | NCT02599649, NCT02530463, NCT03825367, NCT04128020, NCT02397720, NCT03628209, NCT01928576, NCT03259516 | |
| Pembrolizumab | MDS, pancreas cancer, Melanoma, colorectal cancer, AML, NCSLC, ovarian cancer | I, II | NCT03094637, NCT03264404, NCT02816021, NCT02959437, NCT02260440, NCT02845297, NCT04284787, NCT02546986, NCT02900560 | |
| Tremelimumab | Head and neck cancer, MDS | I, II | NCT03019003, NCT02117219 | |
| Decitabine | Avelumab | AML | I | NCT03395873 |
| SHR-1210 | HL, B-cell lymphoma | I, II | NCT03250962, NCT03346642 | |
| Ipilimumab | AML, MDS | II | NCT02890329 | |
| Nivolumab | AML, MDS, lung cancer | I, II | NCT03358719, NCT04277442, NCT02664181 | |
| Pembrolizumab | AML, lymphoma, MDS, breast cancer, NSCLC | I, II | NCT02996474, NCT03240211, NCT03445858, NCT03969446, NCT02957968, NCT03233724 | |
| Guadecitabine | Atezolizumab | Leukemia, AML, MDS | I, II | NCT02935361, NCT02892318 |
| Durvalumab | Kidney cancer, ccRCC, hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, SCLC | I, II | NCT03308396, NCT03257761, NCT03085849 | |
| Ipilimumab | Melanoma, NSCLC | I, II | NCT02608437, NCT04250246 | |
| Nivolumab | Melanoma, NSCLC, colorectal carcinoma | I, II | NCT04250246, NCT03576963 | |
| Pembrolizumab | Lung Cancer, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, NSCLC | I, II | NCT03220477, NCT02901899, NCT02998567 | |
| Tremelimumab | SCLC | I | NCT03085849 |
Abbreviations: DNMTi, DNA methyltransferase inhibitor; ICI, immune checkpoint inhibitor; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; NSCLC, non-small-cell lung carcinoma; HL, Hodgkin lymphoma; ccRCC, clear cell renal cell carcinoma; SCLC, small cell lung cancer.